- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Cervarix.
Displaying page 1 of 2.
| EudraCT Number: 2019-000994-22 | Sponsor Protocol Number: CYD71 | Start Date*: 2019-06-13 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2017-000458-20 | Sponsor Protocol Number: 108160 | Start Date*: 2017-11-14 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A post-marketing surveillance (PMS) study to monitor the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ human papillo-mavirus (HPV) vaccine (Cervarix) in 3,000 healthy female Filip... | ||
| Medical condition: Healthy volunteers (active immunization against Human papillomavirus infection in female subjects for the prevention of cervical cancer). | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2016-002083-13 | Sponsor Protocol Number: HPVfollowup | Start Date*: 2016-07-21 | |||||||||||
| Sponsor Name:Public Health England | |||||||||||||
| Full Title: An observational follow up study of a randomised parallel group phase IV study to evaluate the duration of the immune response to vaccine and non-vaccine HPV types in UK adolescent females who rece... | |||||||||||||
| Medical condition: No specific medical condition - immune reponses to HPV vaccination. | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-006651-39 | Sponsor Protocol Number: 111103 | Start Date*: 2008-12-22 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscular... | ||
| Medical condition: No medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-002340-90 | Sponsor Protocol Number: HPV-Xneutra-001 | Start Date*: 2013-06-26 | |||||||||||
| Sponsor Name:Ghent University Hospital | |||||||||||||
| Full Title: Study of the molecular mechanisms underlying the cross-neutralizing capacity of AS04-adjuvanted HPV vaccine (Cervarix®) in comparison with the aluminiumhydroxyphosphate sulphate adjuvanted HPV vacc... | |||||||||||||
| Medical condition: vaccin against the human papillomavirus | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||
| Trial protocol: BE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-006773-32 | Sponsor Protocol Number: HPV_CSP01 | Start Date*: 2009-05-20 | |||||||||||
| Sponsor Name:Health Protection Agency | |||||||||||||
| Full Title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines | |||||||||||||
| Medical condition: This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate wheth... | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-007876-41 | Sponsor Protocol Number: 111567 | Start Date*: 2008-03-07 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals... | ||
| Medical condition: Cervarix™ is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-020227-48 | Sponsor Protocol Number: 113618 | Start Date*: 2011-01-07 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1... | ||
| Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: PT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-007783-14 | Sponsor Protocol Number: 111507 | Start Date*: 2008-04-10 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) co-administrated with GlaxoSmit... | ||
| Medical condition: For the prevention of high grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18 | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | |
| Trial protocol: NL (Completed) SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-000369-44 | Sponsor Protocol Number: 111375 | Start Date*: 2009-03-24 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first v... | ||
| Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-003429-28 | Sponsor Protocol Number: 109823 | Start Date*: 2014-04-28 | ||||||||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
| Full Title: A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) administered intramuscul... | ||||||||||||||||||
| Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||
| Trial protocol: EE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-000757-22 | Sponsor Protocol Number: 114700 | Start Date*: 2011-06-28 | |||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
| Full Title: A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscu... | |||||||||||||
| Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-017282-35 | Sponsor Protocol Number: 113617 | Start Date*: 2010-07-07 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects | ||
| Medical condition: GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Hum... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: GB (Completed) NL (Completed) PT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-011357-41 | Sponsor Protocol Number: 112772 | Start Date*: 2009-07-01 | |||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
| Full Title: A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the fir... | |||||||||||||
| Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000255-50 | Sponsor Protocol Number: 207347 | Start Date*: 2018-03-12 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects who received three ... | ||
| Medical condition: Healthy volunteers (to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of vaccination in the primary study) | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2012-000445-12 | Sponsor Protocol Number: IPAR0001 | Start Date*: 2012-07-17 | |||||||||||
| Sponsor Name:Department off Infectious Diseases, Aarhus University Hospital Skejby, Denmark | |||||||||||||
| Full Title: Immune Response to Bivalent or Quadrivalent Human Papilloma Virus vaccination in Patients with Chronic Renal Failure | |||||||||||||
| Medical condition: Cervical cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-008124-33 | Sponsor Protocol Number: 112024 | Start Date*: 2009-10-07 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregn... | ||
| Medical condition: GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting ... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: FI (Completed) ES (Completed) DE (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-002777-32 | Sponsor Protocol Number: 110659 | Start Date*: 2007-10-23 | |||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
| Full Title: A phase I/II, partially blind, randomized, multicentre, age-stratified, dose-range study in healthy females aged 9 - 25 years to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’... | |||||||||||||
| Medical condition: For active immunization of females for the prevention of cervical cancer by protecting against persistent infections, cytological abnormalities including atypical squamous cells of undetermined sig... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002035-26 | Sponsor Protocol Number: 115411 | Start Date*: 2011-10-21 | |||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||||||||||||
| Full Title: A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent ... | |||||||||||||||||||||||
| Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) SE (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2007-004347-30 | Sponsor Protocol Number: 110886 | Start Date*: 2007-11-07 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine co-administered with GlaxoSmithKline Biolog... | ||
| Medical condition: For active immunization of females from the age of 10 years onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities includi... | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | |
| Trial protocol: SE (Completed) HU (Completed) DK (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
